Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole

Case report and review of the literature

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Hormonal therapy is the mainstay of adjuvant treatment for women with early-stage estrogen receptor-positive breast cancer. Recently, the aromatase inhibitors have moved to the forefront of adjuvant hormonal therapy, however, the adverse effects of these agents are not yet fully understood. It is generally accepted that tamoxifen, but not the aromatase inhibitors, is associated with an increased risk of thrombosis in women with breast cancer. Studies comparing aromatase inhibitors to tamoxifen in the adjuvant setting have reported a lower rate of venous thromboembolism with the aromatase inhibitors, yet the incidence of venous thromboembolism with these new agents is higher than that expected in the general population. Here we report a case of acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole, and review the literature on the incidence of venous thromboembolism during the use of aromatase inhibitors in the adjuvant setting.

Original languageEnglish (US)
Pages (from-to)249-255
Number of pages7
JournalBreast Cancer Research and Treatment
Volume99
Issue number3
DOIs
StatePublished - Oct 2006

Fingerprint

Aromatase Inhibitors
Embolism
Lung
Venous Thromboembolism
Tamoxifen
Therapeutics
Breast Neoplasms
Incidence
Estrogen Receptors
anastrozole
Thrombosis
Population

Keywords

  • Anastrozole
  • Aromatase inhibitors
  • Breast cancer
  • Pulmonary embolus
  • Venous thromboembolism

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{a56f31d55d994caead0661596ae85e8e,
title = "Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature",
abstract = "Hormonal therapy is the mainstay of adjuvant treatment for women with early-stage estrogen receptor-positive breast cancer. Recently, the aromatase inhibitors have moved to the forefront of adjuvant hormonal therapy, however, the adverse effects of these agents are not yet fully understood. It is generally accepted that tamoxifen, but not the aromatase inhibitors, is associated with an increased risk of thrombosis in women with breast cancer. Studies comparing aromatase inhibitors to tamoxifen in the adjuvant setting have reported a lower rate of venous thromboembolism with the aromatase inhibitors, yet the incidence of venous thromboembolism with these new agents is higher than that expected in the general population. Here we report a case of acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole, and review the literature on the incidence of venous thromboembolism during the use of aromatase inhibitors in the adjuvant setting.",
keywords = "Anastrozole, Aromatase inhibitors, Breast cancer, Pulmonary embolus, Venous thromboembolism",
author = "Jennifer Lycette and Shiuh-Wen Luoh and Beer, {Tomasz (Tom)} and Thomas Deloughery",
year = "2006",
month = "10",
doi = "10.1007/s10549-006-9212-1",
language = "English (US)",
volume = "99",
pages = "249--255",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole

T2 - Case report and review of the literature

AU - Lycette, Jennifer

AU - Luoh, Shiuh-Wen

AU - Beer, Tomasz (Tom)

AU - Deloughery, Thomas

PY - 2006/10

Y1 - 2006/10

N2 - Hormonal therapy is the mainstay of adjuvant treatment for women with early-stage estrogen receptor-positive breast cancer. Recently, the aromatase inhibitors have moved to the forefront of adjuvant hormonal therapy, however, the adverse effects of these agents are not yet fully understood. It is generally accepted that tamoxifen, but not the aromatase inhibitors, is associated with an increased risk of thrombosis in women with breast cancer. Studies comparing aromatase inhibitors to tamoxifen in the adjuvant setting have reported a lower rate of venous thromboembolism with the aromatase inhibitors, yet the incidence of venous thromboembolism with these new agents is higher than that expected in the general population. Here we report a case of acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole, and review the literature on the incidence of venous thromboembolism during the use of aromatase inhibitors in the adjuvant setting.

AB - Hormonal therapy is the mainstay of adjuvant treatment for women with early-stage estrogen receptor-positive breast cancer. Recently, the aromatase inhibitors have moved to the forefront of adjuvant hormonal therapy, however, the adverse effects of these agents are not yet fully understood. It is generally accepted that tamoxifen, but not the aromatase inhibitors, is associated with an increased risk of thrombosis in women with breast cancer. Studies comparing aromatase inhibitors to tamoxifen in the adjuvant setting have reported a lower rate of venous thromboembolism with the aromatase inhibitors, yet the incidence of venous thromboembolism with these new agents is higher than that expected in the general population. Here we report a case of acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole, and review the literature on the incidence of venous thromboembolism during the use of aromatase inhibitors in the adjuvant setting.

KW - Anastrozole

KW - Aromatase inhibitors

KW - Breast cancer

KW - Pulmonary embolus

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=33748351155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748351155&partnerID=8YFLogxK

U2 - 10.1007/s10549-006-9212-1

DO - 10.1007/s10549-006-9212-1

M3 - Article

VL - 99

SP - 249

EP - 255

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -